NASDAQ:ERNA
Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. reported net income of −$14.1M in fiscal 2025. Free cash flow was −$7.1M, and the diluted share count rose 593.1%.Summary generated from Ernexa Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−686.7%
Debt / equityn/a
Free cash flow−$7.1M
FCF marginn/a
Share count change+593.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 0 | 1 | n/a |
| Operating income | −114 | −33 | −21 | −16 | −9 |
| Net income | −123 | −25 | −22 | −45 | −14 |
| Free cash flow | −24 | −21 | −20 | −16 | −7 |
Recent filings
- 8-KRegulation FD disclosure
Sep 16, 2026 - 8-KDirector or officer change
Sep 16, 2026 - 4Insider transaction report
Sep 1, 2026 - 4Insider transaction report
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KRegulation FD disclosure
Jul 2, 2026 - 8-KResults of a shareholder vote
Jul 2, 2026 - 8-KDirector or officer change
Jun 26, 2026